Biological Psychiatry Cognitive Neuroscience and Neuroimaging

Neural correlates of ibogaine: Evidence from functional neuroimaging of military veterans

Biological Psychiatry Cognitive Neuroscience and Neuroimaging February 1, 2026 Malvika Sridhar, Azeezat Azeez, Andrew Geoly et al.

BackgroundIbogaine was recently found to result in significant functional improvements in treating the sequelae of traumatic brain injury (TBI) among Special Operations Forces veterans (SOVs). In the current study, we used multimodal neuroimaging to elucidate the neural correlates of ibogaine in 30 male SOVs who received ibogaine treatment.MethodsArterial spin labeling and blood oxygen...

DOI: 10.1016/j.bpsc.2026.02.001 Functional neuroimaging Neural activity Functional brain imaging Functional connectivity +2

Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy

Biological Psychiatry Cognitive Neuroscience and Neuroimaging February 9, 2024 Yasmin Schmid, Anya K. Bershad 15 citations

There has been renewed interest in the use of 3,4-methylenedioxy-methamphetamine (MDMA) and serotonergic psychedelics in the treatment of multiple psychiatric disorders. Many of these compounds are known to produce prosocial effects, but how these effects relate to therapeutic efficacy and the extent to which prosocial effects are unique to a particular drug class is unknown. In this article,...

DOI: 10.1016/j.bpsc.2024.02.001 Serotonergic MDMA Prosocial behavior Hallucinogen +1

Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile

Biological Psychiatry Cognitive Neuroscience and Neuroimaging February 1, 2024 Friederike Holze, Nirmal Singh, Matthias E. Liechti et al. 50 citations

Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), all of which are serotonin 2A receptor agonists, are being investigated as potential treatments. This review aims to summarize the current clinical research on these 4 compounds and mescaline to guide future research. Their mechanism(s)...

DOI: 10.1016/j.bpsc.2024.01.007 Mescaline Psilocybin Lysergic acid diethylamide Serotonergic +4

Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation

Biological Psychiatry Cognitive Neuroscience and Neuroimaging July 17, 2023 Flora Moujaes, Nathalie M. Rieser, Christophe Phillips et al. 19 citations

BACKGROUND: Pharmacological and nonpharmacological methods of inducing altered states of consciousness (ASCs) are becoming increasingly relevant in the treatment of psychiatric disorders. While comparisons between them are often drawn, to date no study has directly compared their neural correlates. METHODS: To address this knowledge gap, we directly compared 2 pharmacological methods...

DOI: 10.1016/j.bpsc.2023.07.003 Psilocybin Meditation Default mode network Hypnosis +6

Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine

Biological Psychiatry Cognitive Neuroscience and Neuroimaging November 25, 2022 Artemis Zavaliangos-Petropulu, Noor B. Al-Sharif, Brandon Taraku et al. 27 citations

Major depressive disorder is a highly prevalent psychiatric disorder. Despite an extensive range of treatment options, about a third of patients still struggle to respond to available therapies. In the last 20 years, ketamine has gained considerable attention in the psychiatric field as a promising treatment of depression, particularly in patients who are treatment resistant or at high risk for...

DOI: 10.1016/j.bpsc.2022.11.005 Ketamine Default mode network Major depressive disorder Neuroplasticity +10

Characterizing Thalamocortical (Dys)connectivity Following D-Amphetamine, LSD, and MDMA Administration

Biological Psychiatry Cognitive Neuroscience and Neuroimaging April 29, 2022 Mihai Avram, Felix Müller, Helena Rogg et al. 43 citations

Psychedelics, empathogens, and psychostimulants evoke thalamocortical hyperconnectivity with sensorimotor areas, akin to findings in patients with psychotic disorders.

DOI: 10.1016/j.bpsc.2022.04.003 MDMA Amphetamine Hallucinogen Pharmacology